Results 1 to 2 of 2

Thread: InVivo Therapeutics and Cord Blood America Receive Boost in Support as Geron Changes

  1. #1

    InVivo Therapeutics and Cord Blood America Receive Boost in Support as Geron Changes

    remember, nobody is irreplaceable. That's a good thing.





    InVivo Therapeutics and Cord Blood America Receive Boost in Support as Geron Changes Strategy
    The Bedford Report Provides Equity Research on InVivo Therapeutics & Cord Blood America

    Press Release: The Bedford Report – 3 hours ago



    NEW YORK, NY--(Marketwire -11/21/11)- The stem cell industry lost one of its key players earlier this month when industry pioneer Geron Corporation announced its intention to exit the stem cell research market. The company, which was a leader in stem cell research, intends to focus on its oncology programs instead. Geron's exit has left not only the stem cell industry more wide open, but also the spinal cord injury treatment sector. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides investmhttp://finance.yahoo.com/news/invivo-therapeutics-cord-blood-america-131600442.htmlent research on InVivo Therapeutics Corporation (OTC.BB: NVIV.OB - News) and Cord Blood America Inc. (OTC.BB: CBAI.OB - News). Access to the full company reports can be found at:

    more...

    http://finance.yahoo.com/news/invivo...131600442.html

  2. #2
    Senior Member
    Join Date
    Oct 2010
    Location
    South Devon, UK
    Posts
    537
    Quote Originally Posted by manouli View Post
    remember, nobody is irreplaceable. That's a good thing.





    InVivo Therapeutics and Cord Blood America Receive Boost in Support as Geron Changes Strategy
    The Bedford Report Provides Equity Research on InVivo Therapeutics & Cord Blood America

    Press Release: The Bedford Report – 3 hours ago



    NEW YORK, NY--(Marketwire -11/21/11)- The stem cell industry lost one of its key players earlier this month when industry pioneer Geron Corporation announced its intention to exit the stem cell research market. The company, which was a leader in stem cell research, intends to focus on its oncology programs instead. Geron's exit has left not only the stem cell industry more wide open, but also the spinal cord injury treatment sector. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides investmhttp://finance.yahoo.com/news/invivo-therapeutics-cord-blood-america-131600442.htmlent research on InVivo Therapeutics Corporation (OTC.BB: NVIV.OB - News) and Cord Blood America Inc. (OTC.BB: CBAI.OB - News). Access to the full company reports can be found at:

    more...

    http://finance.yahoo.com/news/invivo...131600442.html
    Good news. I don't follow Geron's reasoning. Are they specifically a cancer research organisation? Rather worrying as stem cells seem to offer so much medical potential.

    My feeling is let Geron get on with it, and we'll wait on how much they do for oncology.
    2010 SCINet Clinical Trial Support Squad Member
    Please join me and donate a dollar a day at http://justadollarplease.org and copy and paste this message to the bottom of your signature.

Similar Threads

  1. Replies: 12
    Last Post: 07-12-2011, 02:09 AM
  2. Replies: 0
    Last Post: 07-07-2011, 08:59 PM
  3. Replies: 11
    Last Post: 04-19-2011, 08:33 PM
  4. Replies: 1
    Last Post: 03-12-2011, 01:20 AM
  5. Cord Blood America Says President Bush Signing Umbilical Cord Blood Bill is a Key to
    By lway2002 in forum Funding, Legislation, & Advocacy
    Replies: 0
    Last Post: 12-22-2005, 06:06 AM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •